Cargando…

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice

Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven their clinical efficacy in diabetic kidney disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palacios-Ramirez, Roberto, Lima-Posada, Ixchel, Bonnard, Benjamin, Genty, Marie, Fernandez-Celis, Amaya, Hartleib-Geschwindner, Judith, Foufelle, Fabienne, Lopez-Andres, Natalia, Bamberg, Krister, Jaisser, Frederic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022039/ https://www.ncbi.nlm.nih.gov/pubmed/35464084 http://dx.doi.org/10.3389/fphys.2022.859812

Ejemplares similares

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020)

Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury
por: Nakamura, Toshifumi, et al.
Publicado: (2022)

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
por: Bamberg, Krister, et al.
Publicado: (2018)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue
por: Lefranc, Clara, et al.
Publicado: (2021)

Electrolyte handling in the isolated perfused rat kidney: demonstration of vasopressin V2-receptor-dependent calcium reabsorption
por: Bamberg, Krister, et al.
Publicado: (2020)

Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
por: Jover, Eva, et al.
Publicado: (2021)

The myeloid mineralocorticoid receptor regulates dermal angiogenesis and inflammation in glucocorticoid‐induced impaired wound healing
por: Nguyen, Van Tuan, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
por: Squire, Iain B., et al.
Publicado: (2022)

Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma
por: Aldaz, Paula, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
por: Zhao, Min, et al.
Publicado: (2019)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
por: Mortensen, Line Aas, et al.
Publicado: (2017)

Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
por: Fels, Benedikt, et al.
Publicado: (2022)

Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues
por: Zola, Marta, et al.
Publicado: (2022)

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
por: Figueroa, Stefanny M., et al.
Publicado: (2023)

The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes
por: Gravez, Basile, et al.
Publicado: (2013)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
por: Crompton, Michael, et al.
Publicado: (2023)

The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity
por: Nielsen, Finn Thomsen, et al.
Publicado: (2013)

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
por: Clemmer, John S., et al.
Publicado: (2019)

Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV
por: Srinivasa, Suman, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
por: Park, Eun Jung, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction
por: Schena, Elisa, et al.
Publicado: (2023)

The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis
por: Bousquet, Elodie, et al.
Publicado: (2012)

Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018)

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
por: Eudy, Rena J, et al.
Publicado: (2011)

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
por: Luther, James M., et al.
Publicado: (2012)

The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli
por: Young, Kymberly D., et al.
Publicado: (2016)

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models
por: Bonnard, Benjamin, et al.
Publicado: (2021)

Two Qatari siblings with cystic fibrosis and apparent mineralocorticoid excess
por: Zahraldin, Khalid, et al.
Publicado: (2015)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0jt8ed9ge59d0kgjqr5qd4db5l